Startseite
Märkte
Charts & Ideen
Algo
Nachrichten
Store
Broker
Herunterladen
Wirtschaftskalender
Handelssignale
WebTerminal
Geben Sie
/
ein, um zu suchen: @user, $symbol
Suche
Einloggen
Eröffnen Sie ein Konto
Deutsch
English
Русский
中文
Español
Português
日本語
한국어
Français
Italiano
Türkçe
ACRS
#2713
Aclaris Therapeutics, Inc.
2.8
7
-8.01%
Sektor:
Basis:
Gewinnwährung:
Tagesspanne
Jahresspanne
Tagesänderung
-8.01%
Monatliche Änderung
-26.41%
6 month change
+56.83%
Jahresänderung
+50.26%
Vorheriger Schlusskurs
3.1
2
Open
2.8
7
Bid
Ask
Low
2.8
7
High
2.8
7
Volumen
58
Märkte
Aktien
Gesundheitswesen
ACRS
Open full chart
Financials
Overview
Finanzbericht
Statistics
Dividends
Quarterly
Annual
Value
Q3, 24
Q4, 24
Q1, 25
Q2, 25
Q3, 25
Q4, 25
TTM
Key stats
Total common shares outstanding
71.43 M
107.92 M
108.28 M
108.33 M
108.35 M
120.6 M
—
Valuation ratios
Enterprise value
34.49 M
243.07 M
135.31 M
128.43 M
180.6 M
343.03 M
787.37 M
Price to earnings ratio
-2.21
-1.45
-0.96
-0.9
-1.2
-5.68
-8.75
Price to sales ratio
2.99
10.24
6.63
6.88
11.02
—
—
Price to cash flow ratio
4.52
9.55
17.6
-325.33
4.83
7.83
-295.07
Price to book ratio
0.14
1.23
0.22
0.23
0.36
3.58
4.4
Enterprise value to EBITDA ratio
-2.7
-29.76
-23.65
-17.68
-24.24
—
—
Profitability ratios
Return on assets %
0.04
0.44
0.08
0.08
0.08
0.12
0.36
Return on equity %
0.06
0.62
0.1
0.12
0.12
0.19
0.54
Return on invested capital %
81.66
—
73.5
78.55
79.22
-40.66
190.61
Gross margin %
84.95
92.35
65.22
71.02
83.69
58.92
278.85
Operating margin %
240.93
1 082.26
1 242.89
1 035.9
519.82
1 755.52
4 554.14
EBITDA margin %
-41.74
39.31
-347.9
-225.66
-60.62
-363.78
-997.97
Net margin %
174.55
1 048.34
1 036.77
868.26
442.98
1 528.57
3 876.59
Liquidity ratios
Quick ratio
—
—
—
—
—
—
—
Current ratio
7.03
3.99
5.06
3.88
3.92
3.36
16.23
Inventory turnover
—
—
—
—
—
—
—
Asset turnover
0.03
0.05
0.01
0.01
0.02
0.01
0.04
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
—
—
—
Per share metrics
Operating cash flow per share
-0.31
0.12
0.11
0.08
0.09
0.11
0.38
EBIT per share
-0.03
0.04
-0.04
-0.03
-0.02
-0.04
-0.13
EBITDA per share
-0.03
0.05
-0.04
-0.03
-0.02
-0.04
-0.13
Total debt per share
—
—
—
—
—
—
—
Cash per share
2.43
2.64
1.56
1.48
1.36
1.24
5.63
Net current asset value per share
1.85
1.63
0.89
0.85
0.82
0.79
3.35
Tangible book value per share
1.82
2.01
1.18
1.07
0.98
0.84
4.07
Working capital per share
1.59
1.22
0.71
0.63
0.61
0.55
2.51
Book value per share
1.82
2.01
1.18
1.07
0.98
0.84
4.07
Nachrichten
Stifel raises Aclaris Therapeutics stock price target to $3 on pipeline
Aclaris Therapeutics (ACRS) Reports Q4 Loss, Lags Revenue Estimates
Aclaris Therapeutics Inc: EPS verfehlt Schätzungen um 0,01 $ - Umsatz schlechter als erwartet
Aclaris Therapeutics Inc earnings missed by $0.01, revenue fell short of estimates
Ionis Pharmaceuticals (IONS) Reports Q4 Loss, Tops Revenue Estimates
Corcept Therapeutics (CORT) Q4 Earnings and Revenues Miss Estimates
Aclaris startet Phase-1b-Studie für Asthma-Medikament ATI-052
Aclaris starts phase 1b trial of ATI-052 in asthma patients
Craig-Hallum stuft Aclaris Therapeutics mit "Buy" ein und sieht 174 % Kurspotenzial
Craig-Hallum initiates coverage on Aclaris Therapeutics stock with Buy rating
Positive Studiendaten: H.C. Wainwright bekräftigt Kaufempfehlung für Aclaris
Aclaris stock gets Buy rating reaffirmed by H.C. Wainwright after positive preclinical results